Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study-Reference-Cited by-同舟云学术

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

Published:2021-11 Issue:11 Volume:9 Page:1266-1274
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Nathan Steven D,Waxman Aaron,Rajagopal Sudarshan,Case Amy,Johri Shilpa,DuBrock Hilary,De La Zerda David J,Sahay Sandeep,King Christopher,Melendres-Groves Lana,Smith Peter,Shen Eric,Edwards Lisa D,Nelsen Andrew,Tapson Victor F

Funder

Pharmaceuticals Bayer

GlaxoSmithKline

United Therapeutics Corporation

Boehringer Ingelheim

American College of Clinical Pharmacy

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference23 articles.

1. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias;Travis;Am J Respir Crit Care Med,2013